Related Experiment Video
Updated: Jun 3, 2026
15:23
Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease
Published on: May 13, 2010
Mapping ApoE/Aβ binding regions to guide inhibitor discovery
Qian Liu1, Wei-hui Wu, Chuan-lin Fang
1Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology, Ministry of Education, Department of Chemistry, Tsinghua University, Beijing, PR China.
Molecular Biosystems
|March 17, 2011
Summary
Researchers identified smaller peptide segments and compounds like Congo Red that block the interaction between apolipoprotein E (ApoE) and amyloid beta (Aβ), offering new therapeutic targets for Alzheimer's disease (AD).
Area of Science:
- Neuroscience
- Biochemistry
- Pharmacology
Background:
- The interaction between apolipoprotein E (ApoE) E4 isoform and amyloid beta-peptide (Aβ) is a key factor in Alzheimer's disease (AD) pathogenesis.
- Existing therapeutic strategies are limited, necessitating novel approaches targeting protein-protein interactions in AD.
Purpose of the Study:
- To identify smaller, druggable regions within ApoE and Aβ responsible for their interaction.
- To discover novel inhibitors that can block the ApoE/Aβ interaction for potential AD treatment.
Main Methods:
- Peptide mapping to identify critical interaction domains between ApoE and Aβ.
- Rational design and modification of peptide inhibitors to enhance binding affinity.
- Screening of small molecules, including Congo Red and X-34, for inhibitory activity against ApoE/Aβ interaction.
Main Results:
- Identified specific peptide segments within ApoE and Aβ crucial for their interaction.
- Developed modified peptides demonstrating substantial inhibition of ApoE/Aβ binding.
- Discovered that Congo Red and X-34 effectively inhibit ApoE/Aβ interaction, potentially by targeting Aβ self-interaction regions.
Conclusions:
- The study provides a refined understanding of the ApoE/Aβ interaction interface.
- Identified novel peptide and small molecule inhibitors that antagonize ApoE/Aβ binding.
- These findings offer promising therapeutic avenues for developing new treatments for Alzheimer's disease.
